CareZ™
Welcome to a Community That CareZ
Finding out you have Alpha-1 can be a life-changing moment. That's why CSL Behring
created CareZ—a community of people and services focused on providing the
support you need to help you cope with your condition and help you live your life
to the fullest. At CareZ, you'll find information on:
- Financial support, including insurance assistance, cost-sharing programs, and the
CSL Behring AssuranceSM program
- Emotional support, including Patient Support Specialists and Personal Mentors
- Physical fitness, including the My Steps for Healthy Living program
- The causes, genetics, and treatment of Alpha-1
To learn more, visit CareZ today
Important Safety Information
Alpha1-Proteinase Inhibitor (Human), Zemaira® is indicated for chronic augmentation and maintenance therapy for adults with alpha1-proteinase inhibitor (A1-PI) deficiency and emphysema. Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira are not available.
Zemaira may not be appropriate for the following adult individuals as they may experience severe reactions, including anaphylaxis: individuals with a known hypersensitivity and/or history of anaphylaxis or severe systemic reaction to A1-PI products or their components, and individuals with selective IgA deficiencies who have known antibodies against IgA.
In clinical studies, the following treatment-related adverse reactions were reported in 1% of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling), and pruritus (itching).
Zemaira is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.
Please see full prescribing information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.